finding,pubmed_id,finding_id
"The vaccine candidate Bexsero received breakthrough therapy designation from the FDA for the prevention of meningococcal B disease, which affects over 20,000 people annually in the US, particularly in university campuses.",PMC5396245,PMC5396245_0
"The vaccine candidate RLP2086 received breakthrough therapy designation from the FDA for the prevention of invasive meningococcal B disease, which affects over 20,000 people annually in the US, particularly in university campuses.",PMC5396245,PMC5396245_1
"A novel method rapidly developed vaccines against previously unknown viruses, such as MERS-CoV and SARS-CoV, using a major surface spike (S) protein, formulated using Novavax's proprietary recombinant nanoparticle vaccine technology, blocked infection in preclinical studies.",PMC5396245,PMC5396245_2
"MERS-CoV, which appeared suddenly and caused severe illnesses in humans, blocked infection in preclinical studies using a vaccine candidate against previously unknown viruses, such as MERS-CoV and SARS-CoV, developed on a similar platform.",PMC5396245,PMC5396245_3
"The bacterium Bordetella pertussis, which causes whooping cough, has changed, most likely in response to the vaccine used to prevent the disease, with many strains no longer producing pertactin, a key surface antigen in some current pertussis vaccines. The change in surface protein composition could result in reduced vaccine effectiveness.",PMC5396245,PMC5396245_4
